Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
about
Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future ApplicationsAntipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, BrazilTreating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Therapeutic Body Wraps in Swiss public adult acute inpatient wards. A retrospective descriptive cohort study.Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits.Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials.Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.Risk of weight gain for specific antipsychotic drugs: a meta-analysis.
P2860
Q28552825-8046F3AE-F51D-45FE-95B0-D4ED2B424834Q33560808-AACEB6A5-F8D2-472F-981E-4326EA02507FQ35324015-FCCBC182-0976-49A2-9164-E870AC72404DQ38239613-A94DEE25-2165-4060-9B70-5B77B19EF485Q38972585-C3F3B1B9-4460-4A9E-9CB1-7CB3F61E3ECBQ39062177-C81BC6DA-048B-45B2-B0A7-CFD6F4CDB893Q39812513-F3708EC8-05DF-4F9B-91B3-C2A8F96CED63Q42180852-CC9DEFFD-089C-4E01-A1AD-B4EA0D3F0534Q44897335-29A8FED7-EF65-4A31-BCCB-1327DC873D7AQ48492684-5B9382F6-C197-4D4C-9897-1A719C7A7130Q50540496-52F0C3DA-4A12-4565-96C0-84F02EE21085Q53169797-7F865CA4-B06F-43A1-945F-C22AFCEB9253Q55513508-C3633191-3DE2-40BA-928D-961A7BC57E96
P2860
Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@en
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@nl
type
label
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@en
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@nl
prefLabel
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@en
Antipsychotic polypharmacy and ...... ophrenia: a 5-year comparison.
@nl
P2860
P50
P356
P1476
Antipsychotic polypharmacy and ...... zophrenia: a 5-year comparison
@en
P2093
Chan-Hyung Kim
Jhin-Goo Chang
P2860
P356
10.1177/0004867413488221
P577
2013-05-13T00:00:00Z